SEC v. Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou allegedly engaged in insider trading in advance of an October 28, 2022, public announcement relaying positive news about clinical trials of a cancer fighting drug being developed by Nuvalent, Inc., according to the SEC. The SEC’s complaint further alleges that Ou purchased 80,000 shares of Nuvalent stock after learning of Nuvalent’s planned public announcement.

Summary generated from official Securities and Exchange Commission press release